What is Ecolab's latest dividend and current dividend yield?

What factors drove the changes in Ecolab's revenue and profit?

What were the key takeaways from Ecolab's earnings call?

What is the market's earnings forecast for Ecolab next quarter?

What does Ecolab do and what are its main business segments?

What guidance did Ecolab's management provide for the next earnings period?

Did Ecolab beat or miss consensus estimates last quarter?

What is Ecolab's gross profit margin?

- **Record Growth**: 2025 capped with 15% EPS growth, 18.5% OI margin, and $1.2B free cash flow. 2026 targets 12-15% EPS growth, 19%+ OI margin.
- **High-Tech Dominance**: Global High-Tech ($1B+ in 2025) poised for double-digit growth, driven by Ovivo's ultra-pure water and direct-to-chip cooling solutions.
- **One Ecolab Payoff**: $325M savings target by 2027, enabling 25-50bps SG&A leverage and 100-150bps OI margin expansion.
- **Digital Acceleration**: Ecolab Digital ($400M+ in 2025) growing >20% YoY, with AI solutions like CIP IQ and IQ Suite driving labor savings and efficiency.
- **Margin Ambition**: 30%+ target for Life Sciences, 20%+ for core businesses, and 100-150bps OI margin expansion across the company.

**【CEO Summary Section】**
- **Record Performance**: 2025 marked record highs in sales, margins, EPS, and free cash flow. Q4 2025 saw 15% adjusted EPS growth, driven by accelerating organic sales (3%) and OI margin expansion (140bps to 18.5%).
- **Growth Engines**: 
  - **Global High-Tech**: $1B+ in sales, growing double-digits with 30%+ margins. Direct-to-chip cooling solutions and Ovivo Electronics (ultra-pure water for semiconductors) are key growth drivers.
  - **Pest Elimination**: 7% growth with 1M+ smart devices deployed, targeting 99% best-in-class outcomes.
  - **Life Sciences**: Bioprocessing sales up 75% YoY, targeting 30%+ margins with new purification capacity.
  - **Ecolab Digital**: $400M+ in sales, growing >20% YoY, with AI-driven solutions like CIP IQ and IQ Suite.
- **One Ecolab Initiative**: Savings target increased to $325M by 2027 (from $140M), with $100M+ achieved in 2025. Leverages AI and global COEs for 25-50bps SG&A leverage.
- **2026 Outlook**: 3-4% organic sales growth (accelerating Q4), 100-150bps OI margin expansion, and 12-15% EPS growth. Focus on normalization of institutional distributor inventories and improving basic industries/Paper performance.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - GAAP net income: $420M
  - Non-GAAP EPS: $1.08 (vs. $0.95 consensus)
  - Organic OI margin: 18.5% (up 140bps YoY)
  - Free cash flow: $1.2B (105% of net income)
- **2026 Guidance**: 
  - Reported sales: 7-9% growth
  - Organic sales: 3-4% growth
  - OI margin: 19%+ (100-150bps expansion)
  - EPS: 12-15% growth
- **Financial Highlights**: 
  - 25-50bps SG&A leverage from One Ecolab
  - 75-100bps gross margin expansion from pricing/mix
  - Neutral FX impact assumption
  - 20.5-21.5% tax rate

**【Q&A Highlights】**
- **Volume Growth**: 1% volume growth in Q1 2026, accelerating to 2%+ by year-end. 85% of portfolio growing >3%, offsetting Paper/basic industry headwinds.
- **Global High-Tech**: Ovivo Electronics already secured new fabs; data center liquid cooling solutions align with NVIDIA's Vera Rubin platform. Global High-Tech expected to grow >10% in 2026.
- **Margin Expansion**: 100-150bps OI margin expansion from pricing (2-3%), mix (growth engines), and cost savings (One Ecolab). Life Sciences targeting 30%+ margins.
- **Digital Sales**: Ecolab Digital ($400M+ in 2025) growing >20% YoY, with 100%+ of customer locations to be connected by 2030.
- **CapEx**: 7% of sales in 2026, focused on growth engines like Pest Intelligence, DishIQ, and Global High-Tech.


Ecolab Inc. (ECL) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 4% organic sales growth, with key engines (Pest Elimination +6%, Global High-Tech +25%) driving momentum.
- **Margin Expansion**: Operating margin up 110bps to 18.7%, with 2027 target of 20%.
- **Strategic Acquisitions**: $900M Global High-Tech business post-Ovivo, targeting circular water solutions and direct-to-chip cooling.
- **AI Leadership**: #9 on Fortune AIQ 50 List, enabling 12-15% annual EPS growth.
- **Underperforming Recovery**: Paper and Basic Industries expected to return to growth in 2026 via innovation and One Ecolab cross-selling.

**【CEO Summary Section】**
- Organic sales grew 4% year-over-year, driven by double-digit growth in key growth engines: Pest Elimination (+6%), Life Sciences (+6%), Global High-Tech (+25%), and Ecolab Digital (+25%).
- Breakthrough innovations like Pest Intelligence (400,000+ devices deployed) and 3D TRASAR for AI data centers are delivering 99% pest-free outcomes and 10% power savings for customers.
- Global High-Tech business to expand to $900M post-Ovivo acquisition, targeting circular water solutions for microelectronics and direct-to-chip cooling for AI data centers.
- Operating income margin expanded 110bps to 18.7%, with 2025 full-year OI margin guidance of 18% and 2027 target of 20%.

**【CFO Financial Commentary】**
- Q3 2025 GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $0.95 prior year).
- Adjusted diluted EPS midpoint raised to $7.53 for 2025 (from $7.45), reflecting 12-15% EPS growth in 2026.
- Operating income margin expanded 150bps since 2019, with 20-30bps improvement expected in 2025.
- SG&A leverage of 25-50bps annually through 2027, driven by AI/automation and One Ecolab cross-selling.

**【Q&A Key Highlights】**
- **Global High-Tech Expansion**: Ovivo acquisition to create $900M business with 1,000+ data centers and fabs served, targeting 10%+ annual growth. 1M Pest Intelligence devices expected by mid-2026.
- **Underperforming Businesses**: Paper and Basic Industries expected to return to growth in 2026 via innovation (e.g., power build-outs for AI) and One Ecolab cross-selling ($65B total addressable market).
- **Pricing Strategy**: 2-3% value-based pricing sustained through 2026, with 3%+ achieved in Q3 via trade surcharge and value pricing.
- **AI Leadership**: Ranked #9 on Fortune AIQ 50 List, leveraging AI to improve customer retention (90%+), reduce costs, and drive 12-15% annual EPS growth.
- **Life Sciences Recovery**: Bioprocessing growth to moderate in Q4 (vs. 70%+ last year), but still double-digit; China plant expansion to resolve capacity constraints in 2026.

Ecolab Inc. (ECL) Q3 2025 Earnings Call Transcript

- **Topline Growth**: 3% organic sales driven by 2% value pricing, 4% growth in 85% of business (ex-paper/basic industries).
- **Margin Expansion**: 170bps OI margin expansion to 18%, targeting 20% by 2027.
- **Growth Engines**: Pest Elimination (+6%), Life Sciences (biopharma double-digit), Global High-Tech (+30%) lead the way.
- **Financial Strength**: $1.9B cash, 1.7x leverage, 90%+ FCF conversion.
- **H2 Outlook**: 3% pricing, 12-15% EPS growth, balanced between returns & reinvestment.

**【CEO Summary Section】**
- Organic sales grew 3% Q2, driven by value pricing (2%), core business momentum, and growth engines (Pest Elimination, Life Sciences, Ecolab Digital). 
- 85% of business (excluding paper/basic industries) grew 4% with operating income up 18%.
- Operating margin expanded 170bps to 18%, targeting 20% by 2027.
- Trade surcharge in US implemented, expecting pricing to trend to 3% in H2.
- Growth engines (Pest Elimination +6%, Life Sciences mid-single digits, Global High-Tech +30%) outperformed.
- 2025 EPS guidance maintained at 12-15% growth, balancing returns & reinvestment.

**【CFO Financial Commentary】**
- GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $0.95 prior year).
- Free cash flow conversion ~90%, targeting 95% long-term.
- DPC (delivered product cost) favorable vs. expectations, gross margin +100bps.
- CapEx ~7% of sales, SG&A leverage 20-30bps.
- Strong balance sheet (leverage 1.7x), $1.9B cash on hand.

**【Q&A Highlights】**
- **Pricing**: 2% Q2, targeting 3% in H2 with trade surcharge. Value pricing retention >90%.
- **Pest Elimination**: 6% growth, 20%+ margin expansion via Pest Intelligence. 99% pest-free target in pilot.
- **Supply Chain**: DPC up low-single digits, but net favorable due to supply chain efficiency.
- **Tariffs**: US trade surcharge mitigating ~$100M/year impact. No plans for intl surcharges yet.
- **Free Cash Flow**: Q2 FCF +17% YoY, 65% of net income YTD. Expect 90%+ conversion for full year.
- **M&A Pipeline**: Focused on High-Tech (data centers/microelectronics), Life Sciences, Digital. Disciplined with 2x leverage target.

Ecolab (ECL)-29 Jul 25-2025 Q2 Earnings call transcript

- **Q1 Growth Drivers**: 3% organic sales, 12% EPS growth, 190bps margin expansion. Digital investments key to margin improvement.
- **Trade Surcharge Strategy**: 5% U.S. surcharge to offset tariffs, expected to convert into structural pricing. 2022 energy surcharge precedent shows success.
- **High-Growth Engines**: Global High Tech (30% growth), Ecolab Digital ($80M Q1), Life Sciences (30%+ margin target). Pest Intelligence adoption >1M devices.
- **Balance Sheet Strength**: 1.8x net debt/EBITDA, $140M Q1 buybacks. M&A pipeline active in high-margin adjacents.


**【CEO Opening Remarks】**
- Q1 organic sales grew 3%, driven by new business wins and value pricing. EPS increased 12% to $1.08, outpacing soft end markets.
- Operating income margin expanded 190bps to 19.0%, with digital investments supporting margin expansion.
- 2027 target: 20% operating margin. Near-term focus on mitigating tariffs with a 5% U.S. trade surcharge, expected to fully implement in Q3.

**【CFO Financial Insights】**
- GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $1.05 guidance). Free cash flow conversion target: 90% of net income.
- SG&A as % of sales: 27.0% (down 30bps YoY). Capital allocation: 7% of sales for CapEx, balanced dividend growth and M&A pipeline.

**【Key Business Updates】**
1. **Life Sciences**: Mid-single-digit organic sales growth, 30%+ long-term margin target. Biopharma share gains driven by innovation and capacity expansion.
2. **Pest Elimination**: 5% organic growth, 20%+ margin recovery expected in Q2. Pest Intelligence adoption accelerating with >1M devices deployed.
3. **Global High Tech**: 30% sales growth in water circularity for fabs and data centers. Ecolab Digital: $80M Q1 revenue (12% growth), targeting $320M annualized.
4. **Institutional & Specialty**: I&S segment up 5%, Specialty benefiting from quick-serve restaurant shift. Margins improving as safety investments reduce costs.

**【Q&A Highlights】**
- **Trade Surcharge Impact**: 5% U.S. surcharge to offset $100M+ China tariffs. Expected to convert into structural pricing over time, similar to 2022 energy surcharge success.
- **Demand Trends**: Soft industrial demand stabilized in Q1, but expected to remain challenging. New business pipeline supports +1-2% organic growth.
- **Digital Growth**: Ecolab Digital subscription revenue up 30%, targeting $1B+ by 2030. 100K+ connected devices enable AI-driven savings for customers.
- **Capital Deployment**: $140M Q1 buybacks, 1.8x net debt/EBITDA. M&A pipeline active, focusing on high-margin adjacents like data center cooling.


Ecolab (ECL)-29 Apr 25-2025 Q1 Earnings call transcript

- **Record 2024 Results**: Delivered record sales, profits, and free cash flow with 4% organic growth and 290bps margin expansion.
- **2025 Growth Target**: 12-15% EPS growth driven by U.S. market strength, 2%+ value pricing, and $140M One Ecolab savings.
- **High-Growth Digital Engine**: Ecolab Digital ($300M+ in 2024) to be reported separately, leveraging 100K+ connected systems for AI-driven insights.
- **Data Center Innovation**: Direct-to-chip cooling solutions and water recycling in fabs targeting >20% margins.
- **One Ecolab Acceleration**: 40-50% of 2025 savings front-loaded, with $3B+ cross-sell opportunity in top 35 customers.

**【CEO Opening Remarks】**
- **Record 2024 Performance**: Achieved record sales, earnings, margins, and free cash flow. Organic sales grew 4% in Q4, driven by mid-single-digit growth in the U.S. and low-single-digit growth globally.
- **Margin Expansion**: Organic operating margin increased 150bps in Q4, with full-year margin up 290bps to 16.8%. Targeting 20% operating margin by 2027, with confidence in 18%+ in 2025.
- **2025 Outlook**: Expect 12-15% EPS growth, supported by U.S. market strength, value pricing (2-3%), and cost savings from One Ecolab initiative.
- **Growth Engines**: Data centers, microelectronics, and Ecolab Digital ($300M+ in 2024) are key high-margin growth areas. Digital sales will be reported separately starting Q1 2025.

**【CFO Financial Highlights】**
- **2024 Results**: Adjusted EPS up 15%, free cash flow $2.2B. 2025 capex to sales ratio ~7%, driven by digital and high-tech investments.
- **Currency Impact**: 3% FX tailwind for sales, 4% headwind for EPS. Mitigated by value pricing and accelerated One Ecolab savings.
- **Capital Allocation**: $1B share buybacks in 2024, dividend increased 14%. Strong balance sheet (net leverage 1.7x) supports M&A and organic growth.

**【Key Q&A Takeaways】**
- **Digital Growth**: Ecolab Digital manages 100K+ connected systems, capturing 120B data points annually. Monetizing through device leases, subscriptions, and AI-driven insights.
- **High-Tech Investments**: $300M+ in data centers and fabs, targeting >20% margins. Direct-to-chip cooling solutions and water recycling in fabs are key innovations.
- **One Ecolab Progress**: $140M savings target for 2025, with 40-50% front-loaded. Accelerating cross-sell in top 35 customers ($3B+ opportunity).
- **Pest Intelligence**: Multi-year transition to digital systems, with minimal margin impact. Early success with largest retailer partner.
- **Life Sciences**: $500M+ business with mid-20s OI margin. Investing to reach 25-30% margin with new purification technologies.

Ecolab (ECL)-11 Feb 25-2024 Q4 Earnings call transcript

Ecolab (ECL)-29 Oct 24-2024 Q3 Earnings call transcript

Ecolab (ECL)-30 Jul 24-2024 Q2 Earnings call transcript

Ecolab (ECL)-30 Apr 24-2024 Q1 Earnings call transcript

Ecolab (ECL)-13 Feb 24-2023 Q4 Earnings call transcript

- **Revenue and Margin Strength**: 7% organic sales growth, 18% EPS growth, and 360 basis point gross margin expansion highlight strong execution.
- **Segment Excellence**: Institutional & Specialty near 20% OI margin, Industrial outperforming tough comparisons, and Healthcare showing early restructuring benefits.
- **Future Growth Drivers**: New business wins, digital productivity, and mid-teens 2024 EPS growth underpin long-term margin targets.
- **Financial Discipline**: Working capital improvements, debt reduction, and SG&A efficiency support cash flow and balance sheet strength.

**【CEO Summary Section】**
- **Strong Q3 Performance**: Organic sales grew 7%, meeting expectations, with adjusted EPS up 18% to $1.08, hitting the high end of guidance.
- **Pricing and Margin Expansion**: Value-based pricing drove a 7% increase, while gross margin expanded 360 basis points to 41.3%. Institutional & Specialty segment saw OI margin rise 260 basis points to 19.3%.
- **Segment Strength**: Industrial segment performed well in Food & Beverage and Water, while Healthcare showed improvement with surgical sales. Life Sciences growth was mid-single digits despite market challenges.
- **Future Outlook**: Q4 EPS growth expected at 17-24%, with mid-teens 2024 guidance. Long-term goals include 20% OI margin and 44% gross margin.

**【CFO Financial Commentary】**
- **Working Capital Efficiency**: Q3 working capital improved by $250M, driven by 10-day reduction in days of inventory. Free cash flow conversion expected above 100% for the year.
- **Restructuring Progress**: $26M Q3 restructuring costs, with 90% of a multi-year program expected to complete by end-2024. SG&A headcount down 2%, sales per head up 7%.
- **Debt Management**: Plan to pay down $1B in debt, targeting a 2x leverage ratio by year-end 2024.

**【Q&A Key Highlights】**
- **Institutional Margins**: CEO confident in reaching 20-21% OI margin within a few years, with Q4 OI expected to match 2019 levels.
- **Volume Growth**: Q3 volume flat, but Q4 expected to grow 1%, driven by new business wins in Industrial and Institutional.
- **Healthcare Restructuring**: Early success from bifurcation strategy, with OI improving but still early in the process.
- **Cost Management**: Delivered product costs down 3% YoY, with similar declines expected in Q4 despite 40% higher costs than pre-inflation levels.
- **Digital Productivity**: SG&A productivity gains through automation, with focus on front-line efficiency to support 20% OI margin goal.

Actual																1.13	0.65	1.15	1.23	0.81	1.22	1.38	1.28	0.82	1.1	1.3	1.27	0.88	1.24	1.54	1.55	1.34	1.68	1.83	1.81	1.5	1.89	2.07	2.08
Forecast																1.0634	0.7604	1.1186	1.248	0.8121	1.2089	1.2973	1.3082	0.8257	1.0919	1.3124	1.2519	0.8625	1.2089	1.5233	1.5393	1.336	1.6731	1.8213	1.7975	1.4956	1.8983	2.0708	2.0684	1.6963
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.26%	-14.52%	+2.81%	-1.44%	-0.26%	+0.92%	+6.37%	-2.16%	-0.69%	+0.74%	-0.94%	+1.45%	+2.03%	+2.57%	+1.10%	+0.70%	+0.30%	+0.41%	+0.48%	+0.70%	+0.29%	-0.44%	-0.04%	+0.56%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.58B	2.69B	3.02B	3.07B	2.88B	3.16B	3.32B	3.35B	3.27B	3.58B	3.67B	3.67B	3.57B	3.85B	3.96B	3.94B	3.75B	3.99B	4.00B	4.01B	3.69B	4.03B	4.17B	4.19B	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.50B	2.63B	3.00B	3.12B	2.88B	3.11B	3.27B	3.36B	3.19B	3.49B	3.66B	3.70B	3.48B	3.86B	4.01B	3.94B	3.74B	4.03B	4.03B	3.99B	3.70B	4.02B	4.12B	4.19B	4.02B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.27%	+2.03%	+0.65%	-1.61%	+0.05%	+1.65%	+1.41%	-0.22%	+2.35%	+2.73%	+0.34%	-0.90%	+2.75%	-0.29%	-1.19%	+0.01%	+0.19%	-1.21%	-0.84%	+0.49%	-0.02%	+0.12%	+1.07%	-0.09%	0.00%

ECL

ECL fundamentals

ECL Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

ECL

ECL fundamentals

ECL Q1 2026 Earnings Preview

Earnings Call

ECL Earnings Call Summary for Q1/2026Upcoming Apr 12, 2026

ECL Earnings Call Summary for Q4/20251:00 PM on Feb 10, 2026

ECL Earnings Call Summary for Q3/20251:00 PM on Oct 28, 2025

ECL Earnings Call Summary for Q2/20251:00 PM on Jul 29, 2025

ECL Earnings Call Summary for Q1/20251:00 PM on Apr 29, 2025

You can ask Aime